Stocks
Genmab A/SGMAB
NASDAQHealthcareBiotechnology$26.14-1.62%
Danish biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. Its portfolio includes proprietary oncology drugs and partnerships with major pharmaceutical companies, generating significant royalty revenue from treatments such as multiple myeloma t...
Market Cap: $16.1B52W Range: $17.23 – $35.43
Congressional Interest in Genmab A/S (GMAB)
4 members of Congress have disclosed 12 trades in Genmab A/S (GMAB), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 5 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
12
Unique Politicians
4
Buys
7
Sells
5
Who in Congress Is Trading GMAB?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-01-16 | Josh Gottheimer | buy | $1K – $15K |
| 2024-12-16 | Josh Gottheimer | sell | $1K – $15K |